Heavy metals and chronic diseases: what therapeutic approaches?

Peter Jennrich

IBCMT - International Board of Clinical Metal Toxicology KMT

German Medical Association of Clinical Metal Toxicology

www.tierversuchsfreie-medizin.de

Calcium

- Calcium is the most abundant metal in the human body.
- The average adult body contains about 1 kg.
- Calcium is important for structure and function of the human body.



Calcium - a secondary messenger

As a secondary messenger calcium is important for the cell-regulation by hormons and transmitters

This is important for:

- muscle contraction
- synthesis and secretion of neurotransmitters / hormones
- gene-expression
- regulation of enzyme activity
- regulation of ion pumps

Calcium - a secondary messenger



Calcium uptake in mitochondria



Cell Calcium (Scotland) Nov-Dec 2002, 32(5-6) p363-77



Cell-signals are linked with the ATP production via the Ca(2+) oscillations



Energized mitochondria must expend a significant amount of energy to transport Ca(2+) against its electrochemical gradient from the matrix space to the external space.

Am J Physiol (United States), May 1990, 258(5 Pt 1) pC755-86





Accumulation of calcium into mitochondria play a key role as a trigger to mitochondrial pathology,

especially when the calcium uptake is accompanied by another stressor, in particular ROS or RNS

Duchen MR. Diabetes. 2004 Feb;53 Suppl 1:S96-102.

Peter Jennrich - International Board of Clinical Metal Toxicology

EMF causes altering of intracellular Ca²⁺ homeostasis

This mode of action was further supported by hundreds of studies showing microwave changes in calcium fluxes and intracellular calcium [Ca2+]i signaling.

Pall M. Rev Environ Health. 2015 Apr 16

Extremely low-frequency electromagnetic fields (ELF-EMF) causes various biological effects through altering intracellular calcium homeostasis.

Cui Y, Liu X, Yang T, Mei YA, Hu C. Cell Calcium. 2014 Jan;55(1):48-58.

Together, these findings indicate that ELF-EMF exposure specifically influences the intracellular calcium dynamics of neurons via a calcium <u>channel-independent</u> mechanism.

Luo FL, Yang N, He C, Li HL, Li C, Chen F, Xiong JX, Hu ZA, Zhang J. Environ Res. 2014 Nov;135:236-46



Mimicry of toxic metals



Jennette KW. Environ Health Perspect, Aug 1981, 40 p233-52

Ballatori N. Environ Health Perspect, Oct 2002, 110 Suppl 5 p689-94







Metal-binding agents



Secondary mitochondrial disease caused by toxic metals



Severe CFS
Loss of memory and of cognitive

function

- Dermatitis
- Diminished ability to perform activities of daily living (ADL)

Challenge Test with Chelating agents i.v (zinc trisodium diethylenetriaminepentaacetate - ZnDTPA) (dimercaptopropanesulfonate - DMPS)

Potentially Toxic Metal	Test Result (mcg/g Creatin)	Normal Range (unprovoked)
Aluminum	62,69	< 17
Cadmium	1,56	< 0,5
Lead	44,49	< 1
Mercury	17,61	< 1
Nickel	11,44	< 2,1

ATP intracellular: $0,69 \,\mu M$ (reference value: > $2\mu M$)

Secondary mitochondrial disease caused by toxic metals



Metal-binding agents



ClinicalTrials.gov

TACT – Trial to Access Chelation Therapy

A service of the U.S. National Institutes of Health

- The Trial to Assess Chelation Therapy (TACT) is a randomized, double blind, placebo-controlled, 2×2 factorial clinical trial which is sponsored by the National Institute of Health (NIH).
- It was designed to determine the safety and efficacy of EDTA chelation therapy for individuals with coronary artery disease (CAD) and prior myocardial infarction (MI).

• IMPORTANCE:

- Chelation therapy with disodium EDTA has been used for more than 50 years to treat atherosclerosis without proof of efficacy.
- OBJECTIVE:
- To determine if an EDTA-based chelation regimen reduces cardiovascular events.

ClinicalTrials.gov

A service of the U.S. National Institutes of Health

TACT – Trial to Access Chelation Therapy

CONCLUSIONS AND RELEVANCE:

Among stable patients with a history of MI, use of an intravenous chelation regimen with disodium EDTA, compared with placebo, modestly reduced the risk of adverse cardiovascular outcomes, many of which were revascularization procedures. <u>These results provide evidence</u> to guide further research but are not sufficient to support the routine use of chelation therapy for treatment of patients who have had an MI.

Lamas GA, et al. JAMA 2013 Mar 27;309(12):1241-50.



- Al, Cd, Pb, Ca, Fe, Mg, Co, Cu, Mn, Zn

EDTA binds no mercury and no arsenic

Hindawi Publishing Corporation ISRN Hypertension Volume 2013, Article ID 234034, 15 pages http://dx.doi.org/10.5402/2013/234034



Review Article

The Influence of Arsenic, Lead, and Mercury on the Development of Cardiovascular Diseases

Peter Jennrich

Clinical Metal Toxicologist (IBCMT), Marienstraße 1, 97070 Wuerzburg, Germany

"The cardiovascular effects of arsenic, lead and mercury exposure and its impact on cardiovascular mortality need to be included in the diagnosis and the treatment of CVD." It can be assumed that patients who participated the TACT and had an arsenic and / or mercury load would have benefited from a combination of EDTA and DMPS or DMSA.

Nevertheless, the TACT is a milestone in the recognition of the therapeutic use of chelating substances beyond the treatment of acute metal poisoning.

The use of metal-binding agents should be recognized as necessary for the treatment of diseases which are linked with chronic metal burden from the environment.



Peter Jennrich - International Board of Clinical Metal Toxicology

Heavy metals and chronic diseases: what therapeutic approaches?

CONCLUSION:

The use of chelating substances for the treatment of chronic metal intoxication is a novel therapeutic approach for patients with CFS, MCS and EHS.